On Tuesday, Shares of CVS Health Corp (NYSE:CVS), subtract -0.82% and shut at $73.59 inside the end purchasing and offering session. The last exchanging scope of the stock ranges amongst $72.83 and $74.10. CVS Pharmacy® recently declared noteworthysavings opportunities for ExtraCare® members during its three-day Black Friday sales event at more than 7,900 CVS Pharmacy locations, which kicks off on Thanksgiving Day and runs through Saturday, November 26. For the first time ever, this year’s Black Friday promotion features a generous offer for shoppers to receive $20 in “Christmas Bucks®” when ExtraCare members spend $50 on select seasonal merchandise.
To earn these special rewards, customers simply purchase from participating products like home décor, tree trimming items, ribbons and bows. During the sale, and once the $50 threshold is met, $20 in Christmas Bucks Rewards will right away pay out on the ExtraCare member’s digital or printed receipt. These limited-time Christmas Bucks must be redeemed within two weeks of receipt, and can be used like all ExtraBucks Rewards – as “free CVS money” that can be spent on nearly all non-prescription items in the store.
Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), subtract -2.83% and shut at $17.83 inside the last exchanging session. The rest of the purchasing and offering scope of the stock levels among $17.62 and $18.65. The association’s commercial center capitalization is $6.23 Billion with the general uncommon loads of 341.19 million. Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM) declares its financing plans to facilitate the completion of the acquisition of the North American commercialization rights to RUCONEST® from Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) (“Valeant”), as declared on 9 August 2016.
1 for 7 Rights Issue of 58,943,624 shares to raise about €12.1 million to existing shareholders
Board of Administration to take up their full allotments under the Rights Issue
New $40 million (€37.7 million) straight debt facility from existing lender Silicon Valley Bank and from Kreos Capital V (UK) Ltd Fund
All remaining funding (€62.0 million) from two new convertible bonds with conversion at premiums of between 25% and 35% to the 20 Day Volume Weighted Average Price
Total Funds to be raised in the funding arrangements amount to €111.8 million, resulting in €85 million after transaction costs, fees and repayment of the US$17 million existing debt (€16.2 million)
Net Funds raised (€85 Million) are for payment of the acquisition of the North American commercialisation rights for RUCONEST of US$60 million (€56.7 million) and a total of €28.3 million for additional marketing and sales investments for RUCONEST both in the USA and in the EU.
Total shares issued now will be limited to 58,943,750